Brandon Smaglo, MD, FACP
With a new FDA approval in the third-line setting for patients with gastric cancer and research hinting at the opportunity for a personalized medicine approach, the space is bursting with new data to consider.
State of the Science Summit™ on Gastrointestinal Cancers, which took place just prior to the recent TAS-102 approval, Smaglo highlighted investigational treatment approaches for patients with gastric cancer and called for further research in the adjuvant setting to move the needle forward.
OncLive: Could you discuss the TAGS trial and the key findings?
: TAGS was an interesting trial, largely because it was a study in the very late-line treatment of [patients with] gastric cancer—a third-line of treatment or higher. In many cancers, we do have multiple lines of therapy, but in gastric cancer, we've really been focused a lot on first-line therapy, with only a little bit [of a focus] on second-line treatment. So, to have a study that was focused on that late-line [of therapy] was very unique and it turned out to be very important for the management of our patients.
... to read the full story